Site search
2880 results for '' found
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idio
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idio
/
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NC
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NC
/
A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs) (NCT06139406)
A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs) (NCT06139406)
/
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)
/
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psor
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psor
/
2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)
2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)
/
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein
/
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor
/